PMID- 27466548
OWN - NLM
STAT- MEDLINE
DCOM- 20170125
LR  - 20220321
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 8
DP  - 2016 Aug
TI  - Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic 
      Colorectal Cancer Refractory to Standard Therapies.
PG  - 4299-306
AB  - BACKGROUND: Regorafenib and TAS-102 are novel antitumor agents for patients with 
      metastatic colorectal cancer (mCRC) whose disease has progressed after standard 
      therapies. In randomized trials, regorafenib and TAS-102 prolonged survival in 
      patients with mCRC. However, the appropriate selection of regorafenib or TAS-102 
      in treatment strategy has not yet been established. PATIENTS AND METHODS: We 
      performed a retrospective analysis, between March 2013 and July 2015, on the 
      efficacy and safety of regorafenib or TAS-102. RESULTS: Thirty-seven patients 
      with mCRC treated with regorafenib or TAS-102 were included. Of these 37 
      patients, 23 first received regorafenib and 14 received TAS-102. The median 
      progression-free survival and overall survival were 3.0 and 5.8 months, 
      respectively, in the regorafenib group and 2.1 and 6.3 months, respectively, in 
      the TAS-102 group. Drug-related adverse events (AEs) and grade >/=3 AEs were 23 
      (100%) and 10 (43.5%), respectively, in the regorafenib group and 13 (92.9%) and 
      2 (14.3%), respectively, in the TAS-102 group. The most frequent grade >/=3 AEs 
      were hepatotoxicity (17.4%) and hand-foot syndrome (13.0%) in the regorafenib 
      group, and neutropenia (14.3%) in the TAS-102 group. In subgroup analysis, the 
      median overall survival was 11.5 months in patients receiving crossover treatment 
      with regorafenib to TAS-102, and 7.6 months in those receiving crossover 
      treatment with TAS-102 to regorafenib. CONCLUSION: Our results showed that 
      regorafenib and TAS-102 have comparable efficacy but different toxicity profiles 
      in patients with mCRC. Both are considered new salvage treatment options. 
      Differences in the toxicity profiles between the two treatments will help in 
      choosing regorafenib or TAS-102.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Sueda, Toshinori
AU  - Sueda T
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Sakai, Daisuke
AU  - Sakai D
AD  - Department of Frontier Science for Cancer and Chemotherapy, Osaka University, 
      Graduate School of Medicine, Osaka, Japan dsakai@cfs.med.osaka-u.ac.jp.
FAU - Kudo, Toshihiro
AU  - Kudo T
AD  - Department of Frontier Science for Cancer and Chemotherapy, Osaka University, 
      Graduate School of Medicine, Osaka, Japan.
FAU - Sugiura, Takashi
AU  - Sugiura T
AD  - Department of Medical Oncology, Saito Yukoukai Hospital, Osaka, Japan.
FAU - Takahashi, Hidekazu
AU  - Takahashi H
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Haraguchi, Naotsugu
AU  - Haraguchi N
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Nishimura, Junichi
AU  - Nishimura J
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Hata, Taishi
AU  - Hata T
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Hayashi, Taro
AU  - Hayashi T
AD  - Department of Surgery, Saito Yukoukai Hospital, Osaka, Japan.
FAU - Mizushima, Tsunekazu
AU  - Mizushima T
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Doki, Yuichiro
AU  - Doki Y
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Mori, Masaki
AU  - Mori M
AD  - Department of Gastroenterological Surgery, Osaka University, Graduate School of 
      Medicine, Osaka, Japan.
FAU - Satoh, Taroh
AU  - Satoh T
AD  - Department of Frontier Science for Cancer and Chemotherapy, Osaka University, 
      Graduate School of Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Drug Combinations)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Pyrrolidines)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - 24T2A1DOYB (regorafenib)
RN  - 56HH86ZVCT (Uracil)
RN  - QR26YLT7LT (Thymine)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Drug-Related Side Effects and Adverse Reactions/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Pyrrolidines
MH  - Randomized Controlled Trials as Topic
MH  - Thymine
MH  - Treatment Outcome
MH  - Trifluridine/*administration & dosage/adverse effects
MH  - Uracil/administration & dosage/adverse effects/*analogs & derivatives
OTO - NOTNLM
OT  - Metastatic colorectal cancer
OT  - TAS-102
OT  - regorafenib
EDAT- 2016/07/29 06:00
MHDA- 2017/01/26 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/05/05 00:00 [received]
PHST- 2016/06/13 00:00 [accepted]
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/01/26 06:00 [medline]
AID - 36/8/4299 [pii]
PST - ppublish
SO  - Anticancer Res. 2016 Aug;36(8):4299-306.